About Us
Chairwoman of the Board, Executive Director: Ms. Theresa Tse
-
- Chairwoman of the Board, Executive Director: Ms. Theresa Tse
- Since 2015, she has served as Chairwoman of the Board of Sino Biopharmaceutical Limited and Vice Chairwoman of Chia Tai Pharmaceutical Group. In 2017, she served as the Director of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Vice Chairwoman of Beijing Tide Pharmaceutical Co., Ltd. Ms. Theresa Tse holds a Bachelor of Science Degree in Economics from the Wharton School of the University of Pennsylvania. She has been listed on Forbes' "Top 100 Businesswomen in China" list eight times and was selected for Bloomberg Businessweek's "Bloomberg 50" in 2024.
Since taking office, Theresa Tse has led the company's strategic transformation from generic drugs to innovative drugs, driving business upgrades by increasing R&D investment, building an international R&D platform, and executing a series of capital operations. Theresa Tse actively promotes resource integration and international cooperation. Collaborative projects with multinational pharmaceutical companies such as Boehringer Ingelheim, Shionogi, and Sanofi have advanced rapidly. She has also led several mergers and acquisitions, including the acquisitions of HOB Biotech, LaNova Medicines, and Hygieia Pharmaceuticals, significantly enhancing the company's innovative R&D capabilities and global competitiveness. In recent years, the company's R&D investment as a percentage of revenue has continued to increase. Its R&D pipeline has become one of the largest globally, establishing the company as a major force in global pharmaceutical R&D. Adhering to the philosophy of "Healthy Technology, Warming More Lives", the company focuses on four core therapeutic areas: neoplasm, liver disease, respiratory, and surgery/analgesia, and is dedicated to improving patients' quality of life. As its innovative products enter a period of intensive harvest, Sino Biopharmaceutical Limited will continue to contribute more breakthrough treatment options for patients worldwide.
While adhering to innovative R&D, Theresa Tse leads Sino Biopharmaceutical Limited and its member companies in actively undertaking social responsibilities and participating in various public welfare and charitable activities. She upholds the Charoen Pokphand Group (CP Group)'s business tenet of "Benefiting the Country, the People, and the Enterprise". She also promotes the group's establishment of an Environmental, Social, and Governance (ESG) system centered on "CARE" (Cure, Accessibility, Relationship, Environment) and systematically implements management practices such as carbon neutrality pathway planning, improving medicine accessibility, employee stock incentives, and building a responsible supply chain. In 2025, the Group was the first in China's pharmaceutical industry to release the "Carbon Neutrality Goals and Pathway Plan". It has ranked in the top 6% of global pharmaceutical companies in the S&P Global Corporate Sustainability Assessment (CSA) for two consecutive years and was the only pharmaceutical company selected for the main list of Forbes China's "2024-2025 Sustainable Development Industrial Enterprises".
Under the leadership of Theresa Tse, Sino Biopharmaceutical Limited was included as a constituent stock of the Hang Seng Index in 2018 and became a constituent of the Hang Seng SCHK Biotech 50 Index in 2020. The company has been ranked among the "Top 50 Global Pharmaceutical Companies" by the authoritative US magazine Pharm Exec for seven consecutive years and has been named one of Forbes Asia's "Asia's Fab 50" for three consecutive years. Core enterprises CTTQ Pharma and Beijing Tide Pharmaceutical have been listed on authoritative rankings such as the "Top 100 Chinese Pharmaceutical Companies" and "China's Best Industrial Enterprises in Pharmaceutical R&D Pipelines" for many consecutive years.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Sino Biopharmaceutical Limited Reaches Exclusive Licensing Agreement with Sanofi for Rovadicitinib 2026.03
On March 4, Sino Biopharmaceutical Limited (1177.HK) announced that it has reached an exclusive licensing agreement with Sanofi for Rovadicitinib, a novel, potent, first-in-class (FIC) oral small-molecule JAK/ROCK inhibitor.View > -
Ms. Theresa Tse Named to Forbes China List of Top 100 Outstanding Businesswomen in 2026, Leading the Leapfrog Development of Sino Biopharmaceutical Limited 2026.03
On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation.View > -
Bloomberg Interview | Theresa Tse, Chairwoman of the Board of Sino Biopharm: Driving Innovation Through M&A, Accelerating the Implementation of Globalization Strategy 2026.01
On January 14, following the completion of the major transaction of a RMB 1.2 billion full acquisition of Hygieia, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK), was interviewed by the globally renowned financial media outlet Bloomberg. She elaborated on the strategic significance of this acquisition and answered questions regarding future investment layout, implementation of the globalization strategy, and other topics.View > -
Asian Financial Forum | Theresa Tse: Driving Innovative Achievements with International Potential to the Global Stage 2026.01
From January 26 to 27, the 19th Asian Financial Forum was held in Hong Kong.View > -
.jpg)
Major News! Sino Biopharm Acquires Hygieia for RMB 1.2 Billion, Joins Forces with "Industry Dark Horse" in Small Nucleic Acid to Accelerate Layout in Major Chronic Diseases 2026.01
On January 13, Sino Biopharm (1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.View > -
Ms. Theresa Tse Invited to Attend 2025 International Biomedical Industry Innovation Conference Beijing Forum，Sino Biopharm's Frontier Technology Innovation R&D Center to be Established in International Pharmaceutical Innovation Park 2025.10
On the afternoon of October 25, the plenary session of the 2025 International Biomedical Industry Innovation Conference Beijing Forum was held with the theme "Innovation Without Borders, Health for a Shared Future".View > -
Ms. Theresa Tse Invited to Attend 2025 International Biomedical Industry Innovation Conference Beijing Forum，Sino Biopharm's Frontier Technology Innovation R&D Center to be Established in International Pharmaceutical Innovation Park 2025.10
On the afternoon of October 25, the plenary session of the 2025 International Biomedical Industry Innovation Conference Beijing Forum was held with the theme "Innovation Without Borders, Health for a Shared Future".View > -
Ms. Theresa Tse Attended Qisi Conference: Inflection Point for Domestic M&A in China's Pharmaceutical Industry Has Arrived, Sino Biopharm Embarks on a New Decade 2025.11
On November 25, the 17th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference 2025 (hereinafter referred to as the "Qisi Conference") opened in Beijing.View > -
Xinhua Finance | Sino Biopharm's "Defu Combination" Releases Clinical Study Data 2025.05
Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences stated that the regimen of Benmelstobart combined with chemotherapy followed by sequential combination with Anlotinib has broken through the bottleneck of traditional standard treatments and may change the existing treatment paradigm, providing an innovative first-line treatment model for patients with advanced squamous non-small cell lung cancer who have limited clinical treatment options.View > -
People's Daily Health | Nearly 30 Billion from Out-Licensing Deals! LaNova Medicines Acquired by Sino Biopharm 2025.07
After market close on July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake already acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.View >